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Abstract
The ubiquitin-like modifier ISG15 is one of the most predominant proteins induced by type I interferons (IFN). In this study,
murine embryo fibroblast (MEFs) and mice lacking the gene were used to demonstrate a novel role of ISG15 as a host
defense molecule against vaccinia virus (VACV) infection. In MEFs, the growth of replication competent Western Reserve
(WR) VACV strain was affected by the absence of ISG15, but in addition, virus lacking E3 protein (VVDE3L) that is unable to
grow in ISG15+/+ cells replicated in ISG15-deficient cells. Inhibiting ISG15 with siRNA or promoting its expression in ISG152/
2 cells with a lentivirus vector showed that VACV replication was controlled by ISG15. Immunoprecipitation analysis
revealed that E3 binds ISG15 through its C-terminal domain. The VACV antiviral action of ISG15 and its interaction with E3
are events independent of PKR (double-stranded RNA-dependent protein kinase). In mice lacking ISG15, infection with
VVDE3L caused significant disease and mortality, an effect not observed in VVDE3L-infected ISG15+/+ mice. Pathogenesis in
ISG15-deficient mice infected with VVDE3L or with an E3L deletion mutant virus lacking the C-terminal domain triggered an
enhanced inflammatory response in the lungs compared with ISG15+/+-infected mice. These findings showed an anti-VACV
function of ISG15, with the virus E3 protein suppressing the action of the ISG15 antiviral factor.
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Introduction
Type I interferons (IFN-a and -b) serve a critical role in antiviral
innate immunity and in modulating the adaptive immune response
to infection and tumor development [1]. In response to infection or
Toll-like receptor agonists, IFN is produced and consequently leads
totheup-regulationofhundredsofIFN-stimulatedgenes(ISG)[2,3].
One of the most highly induced genes is ISG15 that encodes a small
UBL protein of 17 kDa that forms covalent conjugates with cellular
proteins [4]. ISG15 is composed of two domains, each of which
carries high sequence and structural similarity to UB (33 and 32%
for the N- and C-terminal domains, respectively) [5,6].
ISG15 conjugation (ISGylation) to substrate proteins occurs in a
manner similar to UB conjugation by utilizing activating,
conjugating and ligating enzymes to facilitate the addition of
ISG15 to specific lysine residues [7]. The ISG15 activating
enzyme is ubiquitin E1 like protein (UBE1L), and the E2 enzyme
for UB conjugation, UbcH8, also recognizes ISG15 [8,9,10].
ISG15 is removed from conjugated proteins by an ISG15-specific
protease, UBP43 (USP18 (UB-specific protease 18)) [11,12,13].
UB as a central cellular regulator and UB-mediated proteolysis
also plays a regulatory role in the immune system [14,15]. While
the degradation by the proteosome generally depends on poly-UB
conjugation, protein modification by ISG15 does not typically
cause substrate degradation [16]. Instead it may alter the
subcellular localization, structure, stability or activity of targeted
proteins [17]. A large number of cellular proteins that are
associated with cellular cytoskeleton, stress response and chroma-
tin remodelling were identified as ISG15 targets. ISG15 also
targets proteins that play a role in the innate antiviral response,
including: PKR, MXA, STAT1, JAK1 and RIG-I [18]. ISGyla-
tion of these antiviral molecules may regulate their activity during
viral infection.
ISG15 expression is almost undetectable under normal conditions
but is strongly up-regulated during viral infections such as human
cytomegalovirus (HCMV), herpes simplex virus (HSV), Sindbisvirus
(SV) and hepatitis C virus (HCV) [19,20,21,22,23,24]. It has been
speculated that the ISG15 up-regulation following viral infection is
involved in different strategies of the antiviral response [25,26].
Some viruses have developed specific strategies to counteract the
activity of the IFN-stimulated genes (ISGs). The influenza B virus
protein NS1B binds ISG15 and blocks protein ISGylation [27].
Furthermore, constitutive expression of ISG15 in type I IFN
receptor knockout (KO) mice confers potent antiviral activity against
SV. This evidence suggests that ISGylation is important for
protecting cells from viral infection [21].
Previously, using cDNA microarrays we described up-regulation
of ISG15 after infection of HeLa cells with the attenuated VACV
strains MVA and NYVAC, an effect not observed after infection
with the virulent strain WR [28,29,30]. Furthermore, the attenuated
mutant VVDE3L that lacks the viral early protein E3 also produces
an increase in the ISG15 mRNA levels [31]. VVDE3L is a virus that
only replicates in IFN-incompetent systems exerting IFN antagonist
activity [32], is nonpathogenic in the mouse model, and provides
protection against a wild-type virus challenge [33,34]. The E3
protein represses the host cell antiviral response by multiple
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enzymes induced by IFN and whose activation triggers a global
inhibition of protein synthesis and virus replication [35,36,37]
through the phosphorylation of eIF-2a (for PKR) and breakdown of
RNA (for RNase L). Significantly, once activated both PKR and
RNase L produced upregulation of ISG15 messenger levels [38,39].
E3 also blocks induction of IFN-a/b through inhibition of
phosphorylation of the transcription factors IRF3 and IRF7
[40,41] and prevention of NF-kB activation [42].
The biological significance of ISG15 mRNA induction in
cultured cells after infection with the VACV mutants and its
repression by the virulent WR is not known. Here we have
investigated the role of ISG15 as an anti-VACV immunity factor
using in vitro and in vivo systems based on MEFs and mice lacking
ISG15. While in MEFs the yields of WR were slightly different
between ISG15+/+ and ISG152/2 infected cells, the non-
replicating VVDE3L in ISG15+/+ cells grew more than one log
better in ISG152/2 cells. Biochemical analyses showed that the
E3 protein interacts with ISG15 through its carboxyl terminal
domain. Repression of ISG15 with siRNAs or expression of ISG15
by a lentivirus vector in ISG15 null cells indicate that VACV
replication can be controlled by ISG15 and that E3/ISG15
protein interaction is independent of the presence of PKR. In mice
lacking ISG15, VVDE3L induced stronger pathogenesis than in
ISG15+/+, an effect similarly triggered by a C-terminal deletion
mutant (VVE3LD26C). Our findings reveal a novel VACV
strategy to counteract the IFN antiviral response through
interaction of the virus E3 protein with ISG15.
Results
Expression of ISG15 is upregulated during infection of
human HeLa and murine embryonic fibroblast cells with
attenuated VACV strains
We and others have previously described upregulation of ISG15
transcript from gene expression profiles of HeLa cells infected with
the attenuated VACV strains, VVDE3L [31], MVA [28] and
NYVAC [30]. This up-regulation was not observed in HeLa cells
infected with the virulent WR [29]. Here, we have validated the
transcriptional changes in ISG15 mRNA levels after VACV
infection by real-time RT-PCR. As shown in Table S1, ISG15
mRNA levels at different times postinfection (p.i.) were enhanced
in HeLa cells infected with the mutant viruses compared to the
virulent WR, in agreement with the microarray data (not shown).
To correlate changes in ISG15 protein levels, we analyzed by
immunoblot the levels of ISG15 in WR- or MVA- or NYVAC- or
-VVDE3L or uninfected MEFs. In agreement with the results of
real time RT-PCR obtained in Hela cells, a clear increase in
ISG15 protein levels was also observed in VVDE3L- or MVA-
infected MEFs cells at 6 and 16 hpi (Fig. 1A). The increase was less
apparent after NYVAC infection probably because overall protein
synthesis is more severely inhibited by NYVAC than MVA [30].
Moreover, the increase of ISG15 protein levels after VVDE3L or
MVA infection required de novo protein synthesis as its
accumulation was prevented by cycloheximide treatment discard-
ing the possibility that infection might increase ISG15 protein
levels by enhancing protein stability (not shown). It should be
noted that there is an increase in the conjugation of ISG15 to its
target proteins after VVDE3L, but reduced in levels after MVA
infection (Fig. 1A). The findings of Fig. 1 establish a clear up-
regulation of ISG15 by the attenuated VACV mutants.
ISG15 has an anti-VACV role and modulates VVDE3L
replication in cultured cells
Since the increase in ISG15 in Hela cells correlated with the
attenuated phenotype of several VACV strains, we next examined
the role of ISG15 in VACV replication using primary MEFs derived
from ISG15+/+ and ISG152/2 mice. While the cytopathic effect
(CPE) observed in ISG152/2 after WR infection (0.1 PFU/cell,
24 h) was similar to ISG15+/+ cells (Fig. 2A, upper panels), the CPE
in ISG152/2 cells after VVDE3L infection was markedly
increased with respect to that observed in ISG15+/+ cells (Fig. 2A,
lower panels). The virus titers for WR were slightly increased in
ISG152/2 compared to ISG15+/+ cells (Fig. 2B), while the yields
of VVDE3L were increased in the ISG152/2 compared to
ISG15+/+ cells (about 25-fold higher). The increase in virus titers
correlated with increase in cellular mortality, as shown in Fig. 2A.
The findings of Fig. 2 suggest that E3 expression might be
suppressing ISG15 function. To define the breath of the E3 anti-
ISG15 activitywe analyzed the roleofanother antiviral factor,PKR,
using MEFs derived from PKR2/2 mice. Both the difference in
CPE and virus yields between VVDE3L infected ISG152/2 and
PKR2/2 cells were clearly distinct (Fig. 1A), indicating that the in
vitro replication of VVDE3L in ISG152/2 is a process independent
ofPKR.WithPKR+/+cellstheCPEandvirusyieldsweresimilaras
for ISG15+/+ cells (not shown).
To provide further evidence for a VACV antiviral role of
ISG15, we used siRNA to specifically block ISG15 mRNA
production. Using siPORT Amine as a transfection reagent, MEFs
were transfected with two specific ISG15 siRNAs (siRNA1 or
siRNA2), or with a specific GAPDH siRNA (positive control) or
with a scrambled siRNA (negative control). Twenty four hours
after transfection cells were infected with WR or VVDE3L
(0.1 PFU/cell), and ISG15 expression, CPE and virus titers were
evaluated during the course of infection. As shown in Fig. 3A, the
two ISG15 siRNAs decreased the expression of ISG15 by over
80% after 24 h of transfection (Fig. 3A). The decrease in ISG15
protein levels was accompanied by an enhanced CPE in VVDE3L
infected ISG15+/+ cells (Fig. 3B); the difference in CPE was less
clear in WR-infected cells. In addition, viral titers were enhanced
in silenced ISG15+/+ cells infected with WR or VVDE3L
(Fig. 3C). We also performed ISG15 mRNA inhibition with
ISG15 siRNAs in PKR2/2 cells and found no changes in CPE
and virus yields for WR and VVDE3L infected cells in comparison
to the results obtained in PKR+/+ cells (not shown), indicating
that the function of E3 protein is independent of PKR activity.
Author Summary
Modification of proteins by ubiquitin (UB) and ubiquitin-
like proteins (UBL) represents a key regulatory process of
innate and adaptive immune responses. Interferon-stimu-
lated gene product 15 (ISG15) is a member of UBL
molecules that can reversibly be conjugated to proteins
mediating considerable antiviral response. In turn, many
viruses, including poxviruses, have evolved strategies to
block the antiviral and inflammatory effects of innate
immune responses to keep cells alive until virus replication
is completed. Here, a novel viral immune evasion
mechanism that inhibits ISG15-dependent antiviral path-
way is described. Vaccinia virus (VACV) pathogenesis in
ISG15+/+ versus ISG152/2 mice is linked to the virus E3
protein, blocking the activity of ISG15 through its C-
terminal domain. This effect was independent of PKR
activation. ISG15 controls the inflammatory response
regulating cytokine levels. Our findings support a new
strategy for poxviruses to evade the host antiviral response
through interaction of the virus E3 protein with ISG15.
Antiviral Innate Response, Vaccinia Virus
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by infection with WR or VVDE3L had no significant effect in
either ISG15 protein level, CPE or virus production, indicating the
specificity of ISG15 function. We checked that GAPDH protein
levels were decreased only in the siRNA-GAPDH transfected cells,
as measured by Western blot analysis (not shown). The results of
Fig. 3 revealed that suppression of ISG15 protein levels leads to
enhanced replication of WR and of VVDE3L, further supporting
an anti VACV role of ISG15.
Absence of ISG15 expression is required for efficient
VVDE3L infection in murine cultured cells
To further extend the role of ISG15 expression in VACV
replication, we tested whether ectopic ISG15 expression in
ISG152/2 cells leads to inhibition of WR or VVDE3L viral
growth. Using pRVISG15-ires-GFP, an optimized retroviral vector
that expresses efficiently ISG15 in transduced cells, we evaluated the
CPE (see Fig. S1) and viral growth of WR or VVDE3L. Viral
titrations showed that retroviral transduction of the ISG15 gene in
ISG152/2 cells result in inefficient VVDE3L viral production,
whereas non-transduced ISG152/2 cells infected with VVDE3L
were able to produce infectious viral particles (Fig. 4C, left panel).
Furthermore, yields of VACV infectious virus decreased in the
ISG15-transduced cells in comparison to those that do not express
ISG15 (Fig. 4C, right panel). These findings demonstrate that the
absenceofISG15isessentialfortheproductive infectionof VVDE3L
and the increase in VACV production in murine cultured cells.
To characterize the effect of ISG15 over-expression in WR or
VVDE3L replication in cells with endogenous ISG15, a similar
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Figure 1. ISG15 protein levels are upregulated during infection of MEFs with the attenuated mutants of vaccinia virus. A. ISG15
protein levels after WR or VVDE3L or MVA or NYVAC infection. MEFs were mock infected (M) or infected at 5 PFU/cell with WR or MVA or NYVAC or
VVDE3L and at the indicated times p.i, cell extracts were analyzed by Western blotting. Equal amounts of proteins were fractionated by SDS-PAGE,
transferred to nitrocellulose paper, and reacted with an antibody that recognizes murine ISG15 protein. On the right, the molecular weight of the
proteins in kilodaltons is indicated. Actin levels showed that the same amount of protein was loaded on the gel. Uninfected cells (M) served as
control. B. Densitometric quantification of ISG15 protein in arbitrary units is indicated. The graphic represents these measurements in three
independent experiments.
doi:10.1371/journal.ppat.1000096.g001
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tion of ISG15+/+ cells, followed by measurements of WR or
VVDE3L viral growth. As shown in Fig. 4, panels C–D, both
viruses showed a decrease in infectious virus production in
correlation with higher ISG15 expression levels. This experiment
supports that ISG15 is a negative regulator of VACV replication.
E3 interacts with ISG15 through its carboxy-terminal
domain
It has been described that the influenza B virus protein NS1B
inhibits ISGylation after binding through its amino terminal
domain to ISG15 [27,43]. To test whether E3 protein, that
contains a similar domain to NS1, is able to bind to ISG15
protein, we performed immunoprecipitation (IP) assays in PKR+/
+ cells using the following different viruses: WR, MVA, VVDE3L
lacking the entire E3L gene, and two deletion mutants
VVE3LD83N and VVE3LD26C with truncated versions of E3L
gene at the N and C-terminus [44]. After ISG15 IP, the entire E3
protein binds efficiently to ISG15 and the N-terminal mutant
D83N, that lacks 83 aminoacids and the PKR binding domain,
binds efficiently to ISG15 (Fig. 5A). In contrast, the C-terminal
mutant D26C, that lacks 26 aminoacids and the ability to bind
dsRNA, does not bind ISG15 (Fig. 5B). We also performed the
reverse IP using an anti-E3 antibody and only the E3 protein that
lacks the C- terminus fails to be immunoprecipitated (Fig. 5B, left
panel). When IP was performed without antibody or using a pre-
immune serum as a control, no interaction was observed (Fig. 5B,
central panels). To analyze if RNA was involved in E3/ISG15
interaction, we treated the IP complex with RNase just before its
loading in the SDS-PAGE, and found that the complex was
destroyed, as no interaction was observed with any of the E3
proteins from the different viruses (Fig. 5B, left panel). This result
indicate that RNA, and probably dsRNA, has a role as a linking
component in the interaction between E3 and ISG15 proteins as
its degradation abolishes the binding of both proteins. ISG15/E3
protein interaction was confirmed by confocal microscopy, as WR-,
or MVA- or VVE3LD83N-infected MEFs showed co-localiza-
tion between ISG15 and E3, while VVDE3L- or VVE3LD26C-
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Figure 2. Effect of ISG15 on cytotoxicity and virus growth after infection of MEFs with virulent and E3L deletion VACV mutant
viruses. A. ISG152/2, PKR2/2 or wild type cells were mock-infected or infected at 0.1 PFU/cell with WR or VVDE3L. At different times p.i, the CPE in
the cells was examined by phase-contrast microscopy. B. Virus growth of WR and VVDE3L infected (0.1 PFU/cell) ISG15+/+, or ISG15 2/2, or PKR2/2
cells. At different times cells were harvested and virus yields were determined by plaque assay for WR or by immunostaining for VVDE3L.
doi:10.1371/journal.ppat.1000096.g002
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the presence of PKR was relevant for this interaction by performing
both IP and confocal experiments in PKR2/2 cells. Both
approaches indicate that the interaction between ISG15 and E3 is
independent of PKR, as in its absence the entire E3 and the protein
that lacks the amino terminus are able to interact with ISG15
(Fig. 5D). The findings of Fig. 5 reveal that ISG15 binds the E3
proteinina PKR-independent mannerand that binding requires the
C-terminal domain of E3 spanning the RNA-binding site, which
suggests that dsRNA acts as a linker.
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Figure 4. Effect of ISG15 overexpresion on virus growth after infection of MEFs with virulent and E3L deletion VACV mutant
viruses. A–B. ISG152/2 MEFs were transduced with high-titer viral supernatants corresponding to the pISG15-ires-GFP retroviral vector. Levels of
ISG15 were measured by Western blot using a specific murine anti-ISG15 antibody. Viral protein E3 levels were measured as control of infection and
levels of eIF2a were used as a loading control. Virus growth of WR and VVDE3L were determined by plaque assay or by immunostaining. C–D.
ISG15+/+ MEFs were transduced as above. Levels of ISG15 were measured by Western blot using a specific murine anti-ISG15 antibody. Viral protein
E3 levels were measured as control of infection and levels of eIF2a were used as a loading control. Virus growth of WR and VVDE3L were determined
by plaque assay or by immunostaining. Control indicates the non-transduced MEFs.
doi:10.1371/journal.ppat.1000096.g004
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infection
To further show that ISG15 is a biological relevant antiviral
molecule against VACV infection, we next evaluated the
susceptibility of ISG152/2 mice to the virus. Thus, we infected
by the intraperitoneal (i.p) route ISG152/2 or ISG15+/+ mice
with WR at 2610
7 or with the attenuated VVDE3L at 10
8 PFU/
mouse and scored for prominent indicators of viral pathogenesis
(weight loss and mortality). While there was reduced weight loss in
ISG152/2 mice, survival was similar between both groups (Fig. 6,
panel A and B). However, after VVDE3L infection the ISG152/
2 mice displayed signs of disease within 2 days, characterized by
ruffled fur and lack of activity, and 25% of the animals died within
1 to 2 days. Half of the mice infected with VVDE3L appeared sick
at 4 days p.i., and 75% recovered after 7 to 8 days p.i. (Fig. 6C–D).
We did not observe virus yields for ISG152/2 or ISG15+/+ mice
infected with VVDE3L in liver or spleen, while virus titers were
easily obtained in WR infected mice (not shown).
Since the inflammatory response might explain the rapid signs
of illness in VVDE3L infected ISG15 KO mice, we measured
serum cytokine levels (IL-6, TNF-a, IL-10, MCP-1, IFN-c, and
IL-12 p 70) at early times post infection. In ISG15+/+ mice, IL-6
levels were similar in serum from WR- or VVDE3L- or mock-
infected mice (Fig. 6E). In contrast, ISG152/2 mice infected with
VVDE3L had an 8-fold increase in serum levels of IL-6 compared
with those infected with WR (P,0.01; Fig. 6E). There were no
changes in levels of other cytokines analyzed between the groups
(not shown).
We also examined the extent of protection conferred in animals
pre-immunized with WR or VVDE3L by i.p route. Thus, pre-
immunized mice (as in Fig. 6) were challenged by i.n route with
WR at 2610
7 PFU/mouse. In the case of ISG15+/+ and
ISG152/2 mice pre-immunized mice with WR, the challenge
had little effect on weight loss and signs of illness, clear signs of
protection (Fig. 7A–B). However after WR challenge, VVDE3L
pre-immunized ISG152/2 mice developed weight loss and signs
of sickness which was not observed in ISG15+/+ mice (Fig. 7C–
D). These findings revealed a reduced protection to challenge with
WR conferred by VVDE3L pre-immunized KO mice, indicating
limited adaptive immune response triggered by VVDE3L infection
of ISG15 2/2 mice.
The antiviral effect of ISG15 correlates with control of the
inflammatory response after VACV infection
Since VVDE3L pre-immunized ISG15 KO mice developed
disease transiently after i.n WR challenge and the upper
respiratory tract is a natural route for variola virus infection, we
next evaluated disease progression in ISG15+/+ and ISG152/2
mice after i.n inoculation with WR and several E3L deletion
mutants (VVDE3L; VVE3LD83N and VVE3LD26C). The highly
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Figure 6. Virulence of WR or VVDE3L after infection of ISG15+/+ and ISG152/2 mice. A–B. Mice were inoculated i.p with purified VACV
(2610
7 PFU/mouse) or VVDE3L (10
8 PFU/mouse). Mice were individually weighed daily, and mean percentage weight loss of each group (n=12) was
compared with the weight immediately prior to infection. C–D. Survival rate after i.p inoculation with both viruses. Dead animals were scored daily
and represented as the percentage of surviving animals. P#0.01 in all experiments. E. IL-6 measured by ELISA from serum collected at 3 hpi. Results
represent the mean6SD of pooled samples from 6 mice.
doi:10.1371/journal.ppat.1000096.g006
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were scored for prominent indicators of viral pathogenesis (weight
loss, signs of illness and mortality). After WR or VVE3LD83N
infection, no significant differences in weigh loss and signs of illness
were observed between ISG152/2 and ISG15+/+ mice, although
slight differences in weight loss were observed between both groups
of mice when inoculated with a lower dose of WR (Fig. 8A, upper
panel). Mortality was higher in mice infected with WR, as all mice
died within 7 days in the case of WR, while infection with
VVE3LD83N caused 25% mortality (Fig.8A–B). However, clear
differences were observed after i.n. inoculation of VVDE3L or
VVE3LD26C. While ISG15+/+ mice did not show signs of illness at
any times p.i, ISG152/2 mice infected with VVDE3L or
VVE3LD26C showed disease as revealed by clear signs of illness
as soon as 2 days and 25% of the animals died. About half of the
mice infected with VVDE3L or VVE3LD26C appeared sick at 4
days p.i, but 75% of them recovered after 7 to 8 days p.i, (Fig. 8C).
To analyze the status of ISGylation in the infected mice, lungs
were homogenized and conjugation of ISG15 to its target proteins
was determined by Western blot. While, ISG152/2 mice do not
express ISG15 (Fig. 7A) and lungs homogenates from ISG15+/+
mice had similar amounts of the ISG15 protein, conjugation of
ISG15 to its targets proteins is enhanced in lung extracts from
mice infected with VVDE3L or VVE3LD26C (Fig. 9A). Similar
result was also observed in MEFs infected in vitro with VVDE3L
where high levels of ISG15 conjugates were clearly observed
(Fig. 1A). These findings suggest that E3 blocks conjugation of
ISG15 to its target proteins by its carboxy-terminal domain.
The presence of VACV proteins, as determined by Western
blot, was more evident in lungs of ISG152/2 in comparison to
ISG15+/+ mice infected with WR or the deletion mutant viruses
(Fig. 9B). As expected, appearance of virus in lungs correlated with
the presence of viral proteins in these tissue extracts (Fig. 9B–C).
These results indicate that although the absence of ISG15 has no
effect in the mortality of the mice at a high dose of WR inoculation
(5610
6 PFU/mice; Fig. 8A, middle and lower panel), it has an
effect in the replication of the WR and E3L mutant viruses, as seen
by the different amount of viral protein and virus titers in lung
tissues of ISG152/2 versus ISG15+/+ mice (Fig. 9B–C).
Histological examination of lung tissue showed that ISG15+/+
animals infected with the different mutant viruses had no
inflammatory cells infiltrating the lung parenchyma. In contrast,
lung sections obtained from ISG152/2 mice infected with
VVDE3L or VVE3LD26C presented severe inflammation with
alveolar wall thickening and infiltration of inflammatory cells (see
enlarged sections in Fig. 10). This phenotype was not observed in
WR- or VVE3LD83N- infected ISG152/2 mice (Fig. 10). This
result indicates that in ISG152/2 mice, pathogenesis and
development of an inflammatory response is mediated by the
absence of E3 virus expression. This phenotype was maintained
after VVDE3L and VVE3LD26C pointing to E3 as a major
VACV molecule involved in virus evasion of the IFN-defense
ISG15 antiviral protein.
Discussion
Pro-inflammatory and IFN-stimulated genes (ISGs) represent
essential components of the innate immune response to viral
infection (40). Upon viral entry into cells, ISG induction occurs in
two waves: acute, IFN-independent induction of a subset of ISGs
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WR. Four mice per group were first i.p, immunized with purified WR (2610
7 PFU/mouse) or VVDE3L (10
8 PFU/mouse), and 30 days later animals were
i.n. challenged with 2610
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doi:10.1371/journal.ppat.1000096.g007
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a/b during the initial phase. In many viral infections, IFN-
independent ISG induction is mediated by the IRF-3 phosphor-
ylation, homodimerization, and nuclear translocation. Activated
IRF3, in turn, induces the expression of type I IFN genes, whose
products trigger strong induction of a subsets of ISGs, including
IFN-b which after its release and ligand-binding to its receptor
then initiates IFN-dependent ISG induction via the IFN receptor
and JAK/STAT signaling pathways. IFN-inducible enzymes, like
the 2.5 OAS/RNAse L system, PKR, and M6, are the best
characterized proteins that mediate antiviral action of IFN.
Another protein, ISG15, was first identified as an IFN-stimulated
gene whose expression is induced strongly by IFN-a/b treatment
and can be detected at low constitutive levels in cells [45]. ISG15
A
B
∆
2
6
C
M
W
R
∆
E
3
L
∆
8
3
Ν
∆
2
6
C
ISG15-/- ISG15+/+
M
W
R
∆
E
3
L
ISG15
ISG15
Conjugates
∆
2
6
C
∆
8
3
Ν
∆
2
6
C
ISG15-/- ISG15+/+
∆
E
3
L
M
W
R
M
W
R
C
WR
E3
∆
E
3
L
C
ISG15+/+ ISG15-/-
0
10
20
30
40
50
60
70
80
V
i
r
u
s
 
t
i
t
e
r
s
(
p
f
u
/
g
 
t
i
s
s
u
e
x
 
1
0
-
5
)
W
R
∆
E
3
L
∆
8
3
Ν
∆
2
6
C
W
R
∆
E
3
L
∆
8
3
Ν
∆
2
6
C
90
100
15
MW(Kda)
25
20
MW(Kda)
206
7
20
29
38
119
57
∆
8
3
Ν
∆
8
3
Ν
Figure 9. Viral replication of different VACV strains in infected ISG15+/+ and ISG152/2 mice. A–B. Western blot of ISG15 and of viral
proteins in lung homogenates from ISG15+/+ and ISG152/2 mice. Animals were i.n, inoculated with purified WR (5610
6 PFU/mouse) or VVDE3L
(5610
7 PFU/mouse) or VVE3LD83N (5610
7 PFU/mouse) or VVE3LD26C (5610
7 PFU/mouse) and immunoblots reacted with specific antibodies to
ISG15 and to viral proteins. Each sample represents pools from 2 mice per group. C. Lung homogenates were titrated by plaque assay in BSC40 (for
WR) or by immunostaining in BHK-21 cells (for VVDE3L). Each sample represents pools from 2 mice per group.
doi:10.1371/journal.ppat.1000096.g009
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transduction; ISG15 expression is markedly increased following
viral infection (14, 30, 49), and many viruses encode inhibitors of
the IFN-transduction pathway or specific inhibitors of ISG to
avoid deleterious effects triggered by these cytokines.
Among animal viruses, the poxvirus family contains a large
array of genes which are used by the virus to evade host immune
responses. VACV encodes multiple proteins that interfere with
complement regulatory proteins, with many cytokines and
chemokines, with TLRs (Toll like receptors) and signal transduc-
tion pathways, with apoptosis, and others [46]. One of the VACV
proteins with strong inhibitory activity of IFN-induced pathways is
E3 [47]. E3 represses the host cell antiviral response inhibiting
both PKR and RNaseL, which trigger global inhibition of protein
synthesis and virus replication [35,36,37]. In addition, E3 blocks
the activation of IRF3 [40,41], and effectively prevents the first
wave of type I IFN synthesis. E3 has two domains, an N-terminal
involved in the direct inhibition of PKR, its nuclear localization,
and Z-DNA binding [34,48,49,50], and the C-terminal that
contains the dsRNA-binding domain required for IFN-resistance
and for the broad host range phenotype of the virus [44,51]. It has
been described that VACV lacking E3 (VVDE3L) replicates in
PKR or RNaseL deficient cells [40].
Through the use of microarrays we identified the gene ISG15 as
being induced in the course of infection of human cells with different
strains of VACV [28,29,30]. The attenuated mutant VVDE3L also
produces an increase in ISG15 messenger levels[31]. The reason for
the induction of ISG15 mRNA levels by attenuated viruses (Fig. 1) is
probably due to the activation of several cellular signal transduction
cascades and of host transcription factors [28,30,31]. Since MVA
and NYVAC strains contain the E3L gene, this upregulation may be
independent of E3 expression with induction being likely due to the
increase in IFN-b levels.
In this study we showed that a VACV mutant lacking E3, which
cannot grow in ISG15 WT cells, is able to replicate both in MEFs
cells derived from ISG15 KO mice or in ISG15 silenced cells. In
addition viral titers also increase in the absence of ISG15
indicating that ISG15 has an essential role against infection of
VACV. During infection of MEFs from ISG15 KO or ISG15
depleted cells, the presence of E3 enhances viral production since
the WR titers are greater than those after infection with the
VVDE3L mutant virus. One explanation of this phenotype is that
the mutant virus lacking E3 triggers apoptosis through PKR
activation which, in turn, reduces virus production as previously
described [52]. The role of ISG15 in VACV replication was also
supported by the more abundant VACV infectious virus and viral
Figure 10. Histopathology of lungs from ISG15+/+ and ISG152/2 mice intranasally infected with VACV mutant viruses. Lungs from
ISG15+/+ and ISG152/2 mice i.n inoculated with, WR (5610
6 PFU/mouse) or MVA (5610
7 PFU/mouse) or VVDE3L (5610
7 PFU/mouse) or
VVE3LD83N (5610
7 PFU/mouse) or VVE3LD26C (5610
7 PFU/mouse) were resected, sectioned and stained with hematoxilin and eosin. For each
group of animals representative fields are shown at a magnification of 406 (left panels) and 1006 (right panels). B. Bronchio, BC. Bronchiole, A.
Alveolar sac, V. Vein.
doi:10.1371/journal.ppat.1000096.g010
Antiviral Innate Response, Vaccinia Virus
PLoS Pathogens | www.plospathogens.org 12 July 2008 | Volume 4 | Issue 7 | e1000096proteins produced in lungs of ISG152/2 mice compared with
lungs of ISG15+/+ mice after infection with WR or with the E3L
deletion mutant viruses (Fig. 9B–C).
While the depletion of ISG15 has an effect on VVDE3L mutant
phenotype and restores virus growth, over-expression of ISG15 in
ISG152/2 murine cells using a retroviral transduction system
revert the restricted VVDE3L viral growth. Over-expression of
ISG15 also reduces markedly WR titers reinforcing the idea that
ISG15 plays a role in the control of VACV replication.
Inhibition of ISG15 function by VACV is likely due to its
interaction with VACV E3, as shown by IP and confocal analyses.
This interaction with ISG15 occurs independently of PKR,
through the C-terminal region of E3 and requires RNA. We
have shown that ISG15 controls the in vitro replication of VACV in
a PKR-independent manner, as WR and VVDE3L titers do not
increase in murine PKR2/2 cells in comparison to those
observed in PKR+/+. While in murine cells VVDE3L is able to
replicate in a PKR-independent manner, as also described in
MEFs lacking RNase L [53], in human HeLa cells with PKR
expression suppressed by siRNA, the mutant virus is able to grow
[40]. The differences in cell origin might explain the distinct effect
of the IFN system in the control of VACV replication.
The mutant VVDE3L virus that was able to replicate in
ISG152/2 MEFs (Fig. 2) did not replicate in ISG15 KO mice
(Fig. 7), but surprisingly infection with VVDE3L provokes sickness
and mortality only in ISG152/2 mice. This was probably related
to the strong inflammatory response triggered by the mutant in
ISG15 KO mice, as observed by the increased levels of IL-6 in
serum (Fig. 4E). Although the biological relevance of this
observation remains to be established, it can be suggested, in
view of the functions assigned to ISG15 in the innate immune
response [54], that this molecule plays a role as regulator of IFN-
triggered innate responses during VACV infection. It will be of
interest to know the type of innate response triggered in ISG15
KO mice infected with VVDE3L.
The inability of VVDE3L to cause significant disease in WT
mice is presumably due, at least in part, to induction of type I IFN
that, in turn, leads to up-regulation of antiviral proteins, such as
PKR and 2–5 OAS/RNaseL system. The mutant virus that lacks
the C terminus of E3L gene involved in the dsRNA sequestration
(VVE3LD26C) is completely attenuated in WT mice; however
deletion of the N terminus (VVE3LD83N) reduces pathogenesis
500- to 5,000-fold [33,48]. We extended these in vivo studies using
the i.n route and compared WR and E3L mutant viruses in WT
and ISG15 KO mice. We observed that only after VVDE3L or
VVE3LD26C inoculation (i.n), the mortality of mice was increased
by the absence of ISG15 (Fig. 6). In the case of WR or
VVE3LD83N, there were no differences in mortality of both
viruses in ISG15 KO in comparison to WT mice although viral
replication was enhanced in the lungs of ISG152/2 in
comparison to ISG15+/+ mice. One explanation is that ISG15
is made non functional after infection with these viruses, because
the carboxy-terminal domain of E3 binds to ISG15 and blocks its
activity. These observations are in correlation with the reduced
presence of conjugates in lungs of WT mice infected with WR or
VVE3LD83N, compared with infection by VVDE3L or
VVE3LD26C. Although lung homogenates presented similar
amounts of ISG15 protein, the conjugation of ISG15 to its targets
proteins, was greatly enhanced after infection with VVDE3L or
VVE3LD26C (Fig. 7). This evidence suggests that inhibition of
conjugation of ISG15 is mediated by E3 and this inhibition
requires the presence of the dsRNA binding domain. Similar result
was also observed in MEFs infected in vitro with VVDE3L where
high levels of ISG15 conjugates were clearly observed (Fig. 1A).
The cause of mortality of ISG15 KO mice after infection with
VVDE3L or VVE3LD26C was a massive inflammation of lungs
with alveolar wall thickening and infiltration of cells (Fig. 8). These
results indicate a role of ISG15 in the control of an inflammatory
response by regulating cytokine levels.
Cytokine and chemokine release occurs rapidly in response to
virus infection, with the aim of recruiting inflammatory leukocytes
in order to limit virus replication and spread, and to induce
adaptive immunity. However, prolonged expression of chemokines
in the context of viral infections may be detrimental to the host.
We find that in the absence of ISG15, infection with VVDE3L
produces an increase of IL-6 that correlates with short-term
morbidity and complications that include pulmonary function
abnormalities. Although the mechanisms of this up-regulation
remains to be established, it can be speculated in view of the
functions assigned to ISG15 that it might be involved in the
regulation of cytokine signal transduction, through the stabiliza-
tion of specific signalling components that facilitate the develop-
ment of a correct innate immune response. In this sense a family of
intracellular proteins called suppressors of cytokine signalling
(SOCS) are essential for the regulation of cytokine expression
having a critical role in the regulation of the innate response.
Considering that SOCS-1 and SOCS-3 negatively regulate the
IFN-induced signal cascade, and VACV E3 protein inhibits the
type I IFN response, it is possible that E3 or other viral proteins
may regulate the IFN response by affecting SOCS protein
expression regulating the ISG15 activity by an unknown
mechanism. We have previously demonstrated that although
WR provokes a general downregulation of cellular mRNAs, there
are a discrete number of human genes that are induced selectively
during the course of VACV infection. A variety of these
upregulated genes encode different members of the SOCS family
[29] indicating that probably VACV may modify SOCS protein
expression to manipulate the cytokine pathway and the antiviral
host response. This strategy may be used to reduce the efficacy of
innate and acquired immune responses to infection. However,
WR modification of cytokine or chemokine responses may also be
a mechanism to recruit new targets for infection, or provide new
niches for infection. It has been described that over-expression of
HCV core protein inhibits IFN signalling and induces SOCS-3
expression. SOCS-1 and SOCS-3 proteins have been reported to
inhibit IFN-induced activation of the JAK-STAT pathway and
expression of antiviral proteins, such as M6A [55].
There are similarities between the functions of VACV E3 and
the NS1 dsRNA-binding protein of influenza virus. NS1 blocks
IRF3 phosphorylation and IFNb mRNA induction [56]. In
addition, NS1 is an inhibitor of PKR, suggesting that dsRNA
sequestration is a strategy used by both RNA and DNA viruses to
evade the IFN induction and action [57]. Furthermore NS1B
binds and blocks ISG15 protein inhibiting the ISGylation. The
region of the NS1B protein that is required for this inhibition
includes the domain that binds dsRNA. VACV may have a similar
mechanism of influenza NS1 to evade ISG15 action as well.
We conclude that the cellular ISG15 protein has an essential
role in VACV replication, acting as a negative feedback regulator
of the cytokine signalling pathway and regulating in this way the
innate response. VACV has therefore developed a mechanism to
counteract this antiviral host response through E3. Because
VVDE3L is not lethal to ISG15+/+ mice lacking PKR, RNase
L, and M61 [40], there must be an additional IFN-induced
antiviral pathway(s) effective against viruses, in which ISG15
should play an essential role. Understanding the host responses
triggered by ISG15 and virus mechanisms of escape is necessary
for development of therapies against important human pathogens.
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Cells, viruses and infection conditions
HeLa cells (ATCC) were cultured in Dulbecco’s medium
(DMEM) supplemented with 10% newborn bovine serum (NCS)
and antibiotics (Gibco, http://www.invitrogen.com). ISG152/2
cells and their wild type counterpart were generated by Osiak et al
[58] and cultured in DMEM with 10% fetal calf serum (FCS).
PKR2/2 and their wild type counterpart [59] were cultured in
Dulbecco’s modified Eagle’s medium with 10% FCS. VACV wild-
type Western Reserve strain (WR) was grown on monkey BSC-40
cells (African green monkey kidney cells), purified by sucrose
gradient banding as described (24) and titrated in BSC-40 cells.
MVA and NYVAC, as well as VACV mutant of E3L were grown in
Baby hamster kidney cells (BHK-21), sucrose purified and titrated in
BHK-21 cells by immunostaining as previously described [60].
VACV constructs deleted of E3L (VVDE3L), of the first 83 N-
terminal amino acids of E3L (VVE3LD83N), or of the last 26 C-
terminal amino acids of E3L (VVE3LD26C) were kindly provided
by B. L. Jacobs (University of Arizona, USA) [44,61].
Quantitative Real-Time RT-PCR
RNA (1 mg) was reverse-transcribed using the Superscript first-
strand synthesis system for reverse transcription-PCR (RT-PCR)
(http://www.invitrogen.com). A 1:40 dilution of the RT reaction
mixture was used for quantitative PCR. Primers and probe sets
used to amplify ISG15 was purchased from (http://www.
appliedbiosystems.com). RT-PCR reactions were performed
according to Assay-on-Demand, optimized to work with TaqMan
Universal PCR MasterMix, No AmpErase UNG, as described
[28]. All samples were assayed in duplicate. Threshold cycle (Ct)
values were used to plot a standard curve in which Ct decreased in
linear proportion to the log of the template copy number. The
correlation values of standard curves were always .99%.
Cellular viability assay
Cells were grown in 96-well plates to confluency and infected
with different VACV or VVDE3L viruses at the indicated
multiplicity of infection (MOI) from 0.01 to 10 PFU/cell. At 24
hours post-infection (hpi), the medium was removed and cytolysis
was determined by crystal violet staining as described previously
[62]. The percentage of viable cells was calculated assuming the
survival rate of uninfected cells to be 100%.
Immunoblotting
Murine embryonic fibroblasts (MEFs) were infected in 6-well
plates with WR, or MVA, or NYVAC, or VVDE3L and collected
at indicated hpi in lysis buffer (50 mM Tris-HCl pH 8.0, 0.5 M
NaCl, 10% NP40, 1% SDS). Equal amounts of protein lysates
(100 mg) were separated by 14% or 8% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to nitrocellulose mem-
branes and incubated with antibodies, anti-ISG15 [58], -actin
(http://www.sigmaaldrich.com), -E3 (kindly provided by B.L.
Jacobs) followed by peroxidase-conjugated mouse or rabbit
secondary antibodies. For the in vivo measurement of ISG15,
parental or ISG152/2 mice were infected with WR, VVDE3L,
VVE3LD83N or VVE3LD26C at the multiplicity indicated. Lung
samples were homogenized and mixed with SDS loading buffer
and boiled for 10 min before Western blot analysis. ISG15
expression was detected as previously described with a rabbit
antiserum against ISG15 [58] followed by peroxidase-conjugated
rabbit secondary antibodies. Blots were developed using ECL
(http://www.amersham.com).
Immunoprecipitation analysis
Confluent MEF cells grown in 100 mm plates were treated with
mouse IFN-a (100 units/ml) during 10 hrs and infected at
3 PFU/cell for 16 h with the recombinant viruses indicated and
cells were collected and lysed and clarified supernatant was
incubated with 20 mg of anti-mouse IP beads (http://www.
ebioscience.com) previously incubated with a rabbit antiserum
against ISG15 [58] or against E3 respectively. Immunoprecipitates
were analyzed by SDS-PAGE followed by immunoblot with the
antibody anti-E3 (kindly provided by B.L. Jacobs). The RNase
treatment consisted in an incubation of the IP extracts with 10 mg
of RNAse for 15 min at room temperature.
Viral inoculation of mice and sample collection
The origin of ISG152/2 mice has been described [58].
ISG152/2 and control wild type (WT) C57/BL-6 mice ( 6 to 10
weeks old) were immunized i.n in 25 ml PBS with VACV at 5610
6
or 10
5 PFU/mouse or with VVDE3L or VVE3LD83N or
VVE3LD26 at 5610
8 PFU/mouse. The i.p inoculation was with
VACV at 2610
7 or VVDE3L at 10
8 PFU/mouse in 200 mlP B S .
Animals were sacrificed at various times post-inoculation and spleen,
liver, ovaries and lungs were removed, washed with sterile PBS, and
stored at 270uC. Serum was obtained by retro-orbital bleedings 3
hours post-inoculation and was allowed to clot 1 hour at 37uC; after
leaving samples at 4uC overnight, they were spun down in a
microcentrifuge, and serum removed and stored at 220uC.
Cytokine Analysis
Secreted IL-6 from serum of mice infected i.p with WR or
VVDE3L at the indicated days was measured with the quantitative
human IL-6 (BD Biosciences) according to the manufacturer’s
instructions. Captured IL-6 was quantified at 450 nm with a
spectrophotometer. Triplicate samples were measured in two
independent experiments. Alternatively, serum cytokine levels
were analyzed for IL-6, TNF, IL-10, MCP-1, IFN-c, and IL-12
p 70 by using the cytometric bead array mouse inflammation kit as
indicated by the manufacturer (http://www.BDBiosciences.com).
Transfection of ISG15 siRNA
ISG15-synthetic siRNA (s79221 and s79223), scrambled siRNA
(used as a negative control; s4390843) and GAPDH siRNA (used
as a positive control; s4390849) were purchased from Applied
Biosystems and resuspended in RNase-free H2O. Transfection of
siRNAs targeting each mRNA was carried out according to the
manufacturer’s instructions with some modifications. Murine
ISG15+/+, PKR+/+ and PKR2/2 embryonic fibroblasts were
plated in 12-well plates 18 to 24 h before transfection. On the day
of transfection, RNA-lipid complexes were introduced into each
well of cells (20 nM RNA) by using siPORT Amine transfection
reagent (http://www.ambion.com). The effect of specific siRNAs
on target protein abundance was assessed by Western-blot.
Twenty-four hours after transfection, siRNA-treated and non-
treated control cells were mock-infected or infected with different
WR or VVDE3L viruses at 0.1 PFU/cell and CPE were visualized
by phase-contrast microscopy at the indicated times p.i.
Ectopic ISG15 protein expression by retroviral
transduction
ISG15+/+ and ISG152/2 MEFs were transduced with high-
titer viral supernatants corresponding to the pISG15-ires-GFP
retroviral vector obtained as described [63]. Supernatants were
collected at 48 h after transfection, filtered through a 0.45-mm-
pore-size filter, and supplemented with complete DMEM medium
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repeated each 12 hours three times in presence of polybrene. The
transduction efficiency was evaluated by Western-blot. Twenty-
four hours after retroviral infection treated and non-treated
control cells were mock-infected or infected with different VACV
or VVDE3L viruses at 0.1 PFU/cell and and CPE were visualized
by phase-contrast microscopy at the indicated times p.i.
Immunofluorescence
PKR+/+ and PKR 2/2 embryonic murine fibroblasts
cultured on coverslips were infected with the viruses indicated.
At 16 hpi cells were washed with phosphate-buffered saline (PBS),
fixed with 4% paraformaldehyde (PFA) and permeabilized
(10 min, room temperature) with 0.1% Triton X-100 in PBS,
washed, and blocked with 20% bovine serum albumin (BSA) in
PBS. Cells were incubated (1 h, 37uC) with anti-ISG15, -E3
(mouse antibody kindly provided by B. Moss); coverslips were
washed extensively with PBS and further incubated (1 h, 37uC)
with ToPro (http://www.molecularprobes.com) and appropriate
fluorescein- or Texas Red-conjugated isotype-specific secondary
antibodies. After washing with PBS, coverslips were mounted on
microscope slides using Mowiol (http://www.calbiochem.com).
Images were obtained using a Bio-Rad Radiance 2100 Confocal
Laser microscope (http://www.biorad.com).
Immunohistochemistry
Formalin-fixed lung from mice mock-infected or infected with
WR, VVDE3L, VVE3LN83N or VVE3LN26 was resected,
sectioned and stained with both hematoxilin and eosin as
previously described [64].
Supporting Information
Figure S1 Effect of ISG15 overexpression on virus citotoxicity
after infection of MEFs with virulent and E3L deletion VACV
mutant viruses. A–B. ISG152/2 or ISG15+/+ MEFs were
transduced with high-titer viral supernatants corresponding to the
pISG15-ires-GFP retroviral vector. CPE was visualized by phase-
contrast microscopy at the indicated times p.i.
Found at: doi:10.1371/journal.ppat.1000096.s001 (0.68 MB PDF)
Table S1 Levels of ISG15 mRNA detected by quantitative real-
time RT-PCR after infection of HeLa cells with several VACV
mutants.
Found at: doi:10.1371/journal.ppat.1000096.s002 (0.02 MB PDF)
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